Asia Pharmaceuticals & Healthcare Q4 2018
Multinational innovative pharmaceutical firms will continue to invest heavily in developed Asia Pacific markets due to thestronger regulatory environments and greater ability to afford high-value medicines. However, these markets will no longer providesignificant revenue growth due to aggressive cost-containment. Instead, growth opportunities will be plentiful in emerging markets.We note that due to continued regulatory challenges and a growing focus on cost-efficiency, the vast majority of this growth will bedriven by the generic medicines sector.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook